How Casgevy Works for Sickle Cell Disease and Beta Thalassemia
Casgevy (exagamglogene autotemcel) is an FDA-approved CRISPR/Cas9 gene-edited cell therapy that treats sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) by correcting the genetic defects causing faulty hemoglobin production.[1]
Patients undergo chemotherapy to clear bone marrow stem cells, followed by collection of their own hematopoietic stem cells. These cells are edited in a lab using CRISPR to disable the BCL11A gene, which normally suppresses fetal hemoglobin (HbF) production. Elevated HbF reduces sickling in SCD red blood cells and improves oxygen-carrying capacity in TDT, restoring normal erythropoiesis.[2][3]
Edited cells are infused back into the patient, where they engraft in the bone marrow and produce functional red blood cells. Clinical trials showed 29/44 SCD patients free of severe vaso-occlusive crises for at least 12 months post-infusion, and 42/44 TDT patients transfusion-independent for at least 12 months.[4]
What Happens During the Treatment Process?
Treatment starts with myeloablative conditioning (chemotherapy like busulfan) over 4-7 days to make space in the bone marrow. Stem cells are harvested via apheresis, edited ex vivo (CRISPR targets BCL11A enhancer), expanded, and cryopreserved. Infusion occurs 4-6 weeks later under hospital monitoring for engraftment (typically by day 28). Full effects emerge over 3-12 months as edited cells dominate hematopoiesis.[1][2]
How Effective Is Casgevy in Clinical Data?
In the CLIMB-121 trial for SCD, 94% of 31 evaluable patients had no severe crises for 12+ months; median HbF rose to 38.5%.[4] For TDT (CLIMB-111), 90% of 42 patients achieved transfusion independence lasting 23+ months on average.[3] Long-term data (up to 5 years) shows sustained HbF expression without clonal expansion risks seen in older therapies.[5]
What Are the Main Risks and Side Effects?
Neutropenia (94% of patients) and infections occur during engraftment. Chemotherapy risks include infertility (90%+), secondary malignancies (rare, monitored lifelong), and organ toxicity. Infusion reactions affect 25%; most resolve. No CRISPR off-target edits detected in trials.[1][6] Patients need lifelong monitoring for graft failure or malignancy.
How Does Casgevy Compare to Other Blood Disease Treatments?
Unlike hydroxyurea or blood transfusions (symptomatic relief for SCD/TDT), Casgevy offers potential one-time cure via gene correction. Stem cell transplants work but require donors and carry graft-vs-host risks. Competitors like Lyfgenia (lovotibeglogene autotemcel) use lentiviral vectors to add anti-sickling genes, avoiding CRISPR but with insertional mutagenesis risks. Casgevy's CRISPR precision reduces those concerns.[7]
Who Makes Casgevy and What's the Cost?
Developed by CRISPR Therapeutics and Vertex Pharmaceuticals. List price is $2.2 million for SCD and $3.1 million for TDT in the US, covering manufacturing but not hospitalization.[8] Coverage varies; outcomes justify for severe cases.
When Do Patents Expire for Casgevy?
Core patents on exagamglogene autotemcel extend to 2038-2041, covering CRISPR editing and BCL11A targeting. DrugPatentWatch.com lists 15 US patents, with the earliest expiry in 2037; challenges possible from biosimilar developers.[9]
[1]: FDA Label for Casgevy (Dec 2023). https://www.fda.gov/media/174461/download
[2]: Frangoul et al., NEJM (2021). https://www.nejm.org/doi/full/10.1056/NEJMoa2031054
[3]: Locatelli et al., NEJM (2022). https://www.nejm.org/doi/full/10.1056/NEJMoa2208705
[4]: Vertex/CRISPR Therapeutics Data (2023). https://ir.crisprtx.com/news-releases/news-release-details/casgevy-exagamglogene-autotemcel-approved-us-historic-first
[5]: Gillmore et al., ASH 2023 Abstract.
[6]: EMA Assessment Report (2024). https://www.ema.europa.eu/en/documents/assessment-report/casgevy-epar-public-assessment-report_en.pdf
[7]: FDA Approval for Lyfgenia (2023).
[8]: Vertex Pricing Announcement (2024).
[9]: DrugPatentWatch.com - Casgevy Patents. https://www.drugpatentwatch.com/p/tradename/CASGEVY